Abstract
The small size of CjCas9 can make easier its vectorization for in vivo gene therapy. However, compared to the SpCas9, the CjCas9 is, in general, less efficient to generate indels in target genes. The factors that affect its efficacity are not yet determined. We observed that the CjCas9 protein expressed in HEK293T cells after transfection of this transgene under a CMV promoter was much lower than the SpCas9 protein in the same conditions. We thus evaluated the effect of proteasome inhibitors on CjCas9 protein stability and its efficiency on FXN gene editing. Western blotting showed that the addition of MG132 or bortezomib, significantly increased CjCas9 protein levels in HEK293T and HeLa cells. Moreover, bortezomib increased the level of CjCas9 protein expressed under promoters weaker than CMV such as CBH or EFS but which are specific for certain tissues. Finally, ddPCR quantification showed that bortezomib treatment enhanced CjCas9 efficiency to delete GAA repeat region of FXN gene in HEK293T cells. The improvement of CjCas9 protein stability would facilitate its used in CRISPR/Cas system.
Funder
Canadian Institutes of Health Research
Ataxia Canada
National Ataxia Foundation
Publisher
Public Library of Science (PLoS)
Reference41 articles.
1. The CRISPR system can correct or modify the expression of genes responsible for hereditary diseases;JP Tremblay;Med Sci (Paris).,2015
2. DNA targeting specificity of RNA-guided Cas9 nucleases;PD Hsu;Nat Biotechnol,2013
3. CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo;BL Duchene;Mol Ther,2018
4. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing;A Edraki;Mol Cell,2019
5. CRISPR-SCReT (CRISPR-Stop Codon Read Through) method to control Cas9 expression for gene editing;P Yameogo;Gene Ther,2021